# Vaccine Therapy in Treating Patients With Melanoma

> **NCT00003556** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 15 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** ALVAC-hB7.1
- **BIOLOGICAL:** canarypox-hIL-12 melanoma vaccine

## Key facts

- **NCT ID:** NCT00003556
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-01
- **Primary completion:** 2001-05
- **Final completion:** —
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2013-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003556, "Vaccine Therapy in Treating Patients With Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00003556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*